Opendata, web and dolomites

PREVENT

Prostate cancer extracellular vesicles as biomarkers for nanomedicine treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PREVENT project word cloud

Explore the words cloud of the PREVENT project. It provides you a very rough idea of what is the project "PREVENT" about.

released    samples    predictability    vesicles    standard    genes    cytotoxic    psa    sirnas    preclinical    diagnostic    diagnosis    guided    nanomedicines    employ    therapeutic    therapies    clinical    evaluation    worldwide    altered    candidates    cdx    males    cell    lnps    prevent    tumour    evs    containing    blood    co    resistant    therapy    prostate    prepared    cancer    levels    agent    invasive    disease    microfluidics    fingerprint    curable    urine    efficacy    monitor    reduce    composition    parental    platforms    excitement    intercellular    synergistic    plasma    deadliest    prognosis    stage    antigen    patients    extracellular    exploited    flow    nanoparticles    lethal    combination    bodily    biopsies    docetaxel    treatment    immunodetection    ing    anti    lipid    created    strategy    patient    nanomedicine    crpc    castration    fluids    detected    pc    ultimately    cytometry    biomarker    survival    loaded    immunocapture    communication    liquid    rational    companion    collect    free    cells    drug    types   

Project "PREVENT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 228˙421 €
 EC max contribution 228˙421 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-GF
 Starting year 2015
 Duration (year-month-day) from 2015-09-14   to  2018-09-13

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 228˙421.00
2    UNIVERSITY OF BRITISH COLUMBIA CA (VANCOUVER) partner 0.00

Map

 Project objective

Prostate cancer (PC) is one of the deadliest types of cancer in males worldwide. Early stage PC is often curable but many patients develop castration-resistant prostate cancer (CRPC), resulting in lethal end-stage disease. Prostate specific antigen (PSA) plasma levels have been traditionally exploited for diagnosis and prognosis. However, the application of PSA as a biomarker is associated with predictability issues. Advanced therapies are required for the treatment of CRPC, guided by a reliable companion diagnostic (CDx) test to monitor therapeutic efficacy. The aim of “PREVENT” is to co-develop a nanomedicine-based combination therapy for the treatment of CRPC and a CDx based on extracellular vesicles (EVs). I will employ tumour-targeted nanomedicines to deliver more drug to the tumour and reduce side effects when compared to free drug. The treatment comprises microfluidics-prepared lipid nanoparticles (LNPs) containing siRNAs that target genes involved in CRPC and LNPs loaded with the cytotoxic anti-cancer agent docetaxel to achieve synergistic therapeutic effects. For the CDx test, extracellular vesicles (EVs) have created excitement as possible biomarker candidates. EVs are released by cells as means of intercellular communication and can be detected in bodily fluids. The number of EVs and their composition is altered in CRPC, raising opportunities to exploit them in a CDx test. As EVs provide a fingerprint of their parental cell, EVs can be considered liquid biopsies, providing more information than standard biomarker measurements, and much less invasive than prostate biopsies. I will collect blood and urine samples during the preclinical evaluation of the proposed treatment for analysis using immunocapture and flow cytometry-based immunodetection platforms. The co-development of a nanomedicine combination treatment for CRPC and a CDx test is a rational strategy that has the potential to advance into clinical evaluation and ultimately improve patient survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREVENT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREVENT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ICARUS (2020)

Information Content of locAlisation: fRom classical to qUantum Systems

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

ReSOLeS (2019)

New Reconfigurable Spectrum Optical Fibre Laser Sources

Read More